Top Markets
Coin of the day
Satsuma Pharmaceuticals, Inc. Satsuma Pharmaceuticals, Inc.

Satsuma Pharmaceuticals, Inc.

STSA
Rangering i aksjer #29900
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative therapies for the rapid relief of migraines. Its lead therapeutic candidate, STS101, is an integrated drug-device system comprising a proprietary dry-powder formulation of dihydroergotamine mesylate. Currently, STS101 is progressing through its pivotal SUMMIT Phase 3 efficacy trials and is designed for self-administration via a specialized, pre-filled, single-use nasal delivery device. Established in 2016, the company maintains its headquarters in South San Francisco, California.
Aksjekurs
$1.10
Sist synkronisert: 2023-06-07
Markedsverdi
$19.12M
Endring (1 dag)
-0.90%
Endring (1 år)
0.00%
Land
US
Handel Satsuma Pharmaceuticals, Inc. (STSA)

Kategori

P/S-forhold for Satsuma Pharmaceuticals, Inc. (STSA)
P/S-forhold per 2026 TTM: 0
Ifølge Satsuma Pharmaceuticals, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for Satsuma Pharmaceuticals, Inc. fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
10.17 -
US
10.13 -
NL
2.95 -
AU
- -
CH
- -
KR